Intravenous thrombolytic therapy for acute ischemic stroke: The experience of a community hospital

Acta Neurologica Taiwanica

Volumn 18, Issue 1, 2009, Pages 14-20

  Hsu, Yung Chu ^a   Sung, Sheng Feng ^a   Ong, Cheung Ter ^a   Wu, Chi Shun ^a   Su, Yu Hsiang ^a  

^a CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

Author keywords

Ischemic stroke; Thrombolytic therapy; Tissue plasminogen activator

Indexed keywords

ACETYLSALICYLIC ACID; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGE DISTRIBUTION; ARTICLE; BRAIN HEMORRHAGE; BRAIN HERNIA; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; COMMUNITY HOSPITAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EMBOLISM; EXPERIENCE; FATALITY; FEASIBILITY STUDY; FEMALE; FIBRINOLYTIC THERAPY; FOLLOW UP; HUMAN; MALE; MEDICAL RECORD; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; RANKIN SCALE; RETROSPECTIVE STUDY; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; AGED; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HOSPITALS, COMMUNITY; HUMANS; INJECTIONS, INTRAVENOUS; INTRACRANIAL EMBOLISM; INTRACRANIAL THROMBOSIS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STROKE; TAIWAN; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 63249101746     PISSN: 10196099     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333: 1581-7.
2. Graham GD. Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data. Stroke 2003;34:2847-50.
3. Grond M, Stenzel C, Schmulling S, et al. Early intravenous thrombolysis for acute ischemic stroke in a community-based approach. Stroke 1998;29:1544-9.
4. Katzan IL, Furlan AJ, Lloyd LE, et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA 2000;283:1151-8.
5. Reed SD, Cramer SC, Blough DK, et al. Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischemic stroke treated in community hospitals. Stroke 2001;32:1832-40.
6. Lindsberg PJ, Soinne L, Roine RO, et al. Community-based thrombolytic therapy of acute ischemic stroke in Helsinki. Stroke 2003;34:1443-9.
7. Lien LM, Chen JR, Chen WH, et al. Preliminary experience of treating acute ischemic stroke with intravenous tissue plasminogen activator. Formosan J Med 2000;4:379-87 (in Chinese).
8. Wong WJ, Hu HH, Luk YO, et al. Intravenous thrombolytic therapy in acute ischemic stroke in Taiwan. Taiwan Crit Care Med 2001;3:112-20 (in Chinese).
9. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35-41.
10. Bamford J, Sandercock P, Dennis M, et al. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991;337:1521-6.
11. Sung SF, Chen SH. Neurosurgical removal of intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a case report. Acta Neurol Taiwan 2002; 11:24-7.
12. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-25.
13. Ferro JM. Cardioembolic stroke: an update. Lancet Neurol 2003;2:177-88.
14. Azzimondi G, Bassein L, Fiorani L, et al. Variables associated with hospital arrival time after stroke: effect of delay on the clinical efficiency of early treatment. Stroke 1997;28:537-42.
15. Qureshi AI, Kirmani JF, Sayed MA, et al. Time to hospital arrival, use of thrombolytics, and in-hospital outcomes in ischemic stroke. Neurology 2005;64:2115-20.
16. Yamaguchi T, Mori E, Minematsu K, et al. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke 2006;37: 1810-5.
17. Tanne D, Bates VE, Verro P, et al. Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: a multicenter survey. The t-PA Stroke Survey Group. Neurology 1999;53:424-7.
18. Buchan AM, Barber PA, Newcommon N, et al. Effectiveness of t-PA in acute ischemic stroke: outcome relates to appropriateness. Neurology 2000;54:679-84.
19. Lopez-Yunez AM, Bruno A, Williams LS, et al. Protocol violations in community-based rTPA stroke treatment are associated with symptomatic intracerebral hemorrhage. Stroke 2001;32:12-6.
20. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke 1997;28:2109-18.
21. Larrue V, von Kummer R, del Zoppo G, et al. Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study. Stroke 1997;28:957-60.
22. Ueshima S, Matsuo O. The differences in thrombolytic effects of administrated recombinant t-PA between Japanese and Caucasians. Thromb Haemost 2002;87:544-6.
23. Sane DC, Stump DC, Topol EJ, et al. Racial differences in responses to thrombolytic therapy with recombinant tissue-type plasminogen activator. Increased fibrin(ogen)olysis in blacks. The Thrombolysis and Angioplasty in Myocardial Infarction Study Group. Circulation 1991;83:170-5.
24. Lodder J, Krijne-Kubat B, van der Lugt PJ. Timing of autopsy-confirmed hemorrhagic infarction with reference to cardioembolic stroke. Stroke 1988;19:1482-4.
25. Krijne-Kubat B, Lodder J, van der Lugt PJ. Hemorrhagic infarction on CT in cardioembolic stroke. Clin Neurol Neurosurg 1987;89:103-5.
26. Molina CA, Montaner J, Abilleira S, et al. Timing of spontaneous recanalization and risk of hemorrhagic transformation in acute cardioembolic stroke. Stroke 2001;32:1079-84.
27. Ribo M, Alvarez-Sabín J, Montaner J, et al. Temporal profile of recanalization after intravenous tissue plasminogen activator: selecting patients for rescue reperfusion techniques. Stroke 2006;37:1000-4.
28. Marler JR, Jones PW, Emr M, eds. Setting New Directions for Stroke Care: Proceedings of a National Symposium on Rapid Identification and Treatment of Acute Stroke. Bethesda, Md: National Institute of Neurological Disorders and Stroke, 1997.
29. Demchuk AM, Tanne D, Hill MD, et al. Predictors of good outcome after intravenous tPA for acute ischemic stroke. Neurology 2001;57:474-80.
30. Marler JR, Tilley BC, Lu M, et al. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology 2000;55:1649-55.
31. Ribo M, Molina C, Montaner J, et al. Acute hyperglycemia state is associated with lower tPA-induced recanalization rates in stroke patients. Stroke 2005;36:1705-9.
32. Zangerle A, Kiechl S, Spiegel M, et al. Recanalization after thrombolysis in stroke patients: predictors and prognostic implications. Neurology 2007;68:39-44.
33. Katzan IL, Hammer MD, Hixson ED, et al. Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol 2004;61:346-50.